Please ensure Javascript is enabled for purposes of website accessibility

Horizon's Hostile Bid for DepoMed Is Too Low

By Todd Campbell - Jul 9, 2015 at 7:11AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Horizon Pharma plc's $3 billion offer to acquire DepoMed isn't big enough.

After being stonewalled by DepoMed's (ASRT -0.54%) board of directors, Horizon Pharma plc (HZNP -1.26%) has gone public with a bid to acquire DepoMed for $3 billion.

Horizon Pharma's public announcement could kick-start DepoMed's management into negotiations, or lead to DepoMed making a stronger and more vocal argument to investors on why it should retain its independence. Either way, Horizon Pharma's current bid likely undervalues DepoMed.

Who are these guys?
Neither of these companies is very well known to investors, but both are intriguing businesses that are minting money thanks to a business model that involves acquiring underperforming FDA approved therapies and reinvigorating sales. Horizon Pharma is the bigger of the two companies, with a $5.2 billion market cap, and $113 million in first-quarter sales.

Horizon Pharma's success stems from Vimovo, a pain reliever it acquired in 2013 for $35 million that limits ulcers in arthritis patients. At the time of its acquisition, Vimovo had just $20 million in annual sales, but thanks to Horizon Pharma's relaunch efforts, Vimovo has become a far better selling therapy, with $163 million in sales last year. In the wake of Vimovo's success, Horizon Pharma also acquired Actimmune and Pennsaid last fall, and bought Hyperion Therapeutics for $1.1 billion this past spring.

Across all of these medicines, Horizon Pharma expects to deliver sales of between $590 million and $610 million this year, and that has industry watchers projecting EPS of $1.22 in 2015. DepoMed is smaller than Horizon Pharma, but it has a similar business model that could help it close the gap.

DepoMed markets three fast-growing medicines, including the shingles pain therapy Gralise, the breakthrough pain medication Lazanda, and the migraine drug Cambia. The gem in DepoMed's portfolio, however, is Nucynta, an opioid pain medication that DepoMed acquired from Johnson & Johnson for $1.05 billion earlier this year.

In April, DepoMed relaunched Nucynta with a 275 person sales force and a 44% price hike. The company thinks this will allow it to deliver total companywide sales of between $310 million and $335 million this year.

Is $3 billion enough?
If DepoMed leverages its existing relationships with pain specialists, and boosts Nucynta's market share beyond current levels, Nucynta could prove to be a big moneymaker that isn't fully factored into Horizon Pharma's $3 billion offer. Currently, the original formulation of Nucynta accounts for just 0.3% of the short-acting opioid market, and the longer-lasting Nucynta ER represents just 1.5% of the long-acting opioid market. Because DepoMed pegs sales in the short-term opioid market at $7.1 billion and sales in the long-term opioid market at $5.5 billion annually, small gains in market share could translate into significant revenue growth for DepoMed, especially because the total opioid market is forecast to grow by 5% per year through 2018.

Nucynta's market opportunity is a big reason why industry analysts think that DepoMed's sales will jump to $484 million next year, which is 44% higher than the top-end of DepoMed's 2015 sales guidance. That's significant revenue growth, but Nucynta's impact on the bottom line may be more important to a potential acquirer.

Analysts expect DepoMed to report EPS of $0.29 this year, but DepoMed's ability to leverage Nucynta's sales growth against its fixed costs has investors thinking that DepoMed's EPS will surge to $1.20 in 2016. Although there's no guarantee that Nucynta will be as successful as these forecasts suggest, these projections could mean that Horizon Pharma is willing to increase its offer, especially since Horizon Pharma could eliminate a lot of overlapping costs associated with selling its own pain medicines. DepoMed's growth could also encourage other suitors to come knocking. 

Looking forward
DepoMed has firmly rejected Horizon Pharma's overture, but DepoMed's board has a fiduciary responsibility to evaluate offers, so anything could still happen. Personally, I'm a fan of both DepoMed and Horizon Pharma's business model, and believe that both could offer investors significant growth in the future. For that reason, regardless of how this deal plays out, I think both of these companies could be buys.

Todd Campbell owns shares of DepoMed. Todd owns the equity research firm E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. The Motley Fool recommends Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Horizon Therapeutics Public Limited Company Stock Quote
Horizon Therapeutics Public Limited Company
HZNP
$64.08 (-1.26%) $0.82
Depomed, Inc. Stock Quote
Depomed, Inc.
ASRT
$3.68 (-0.54%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
403%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.